Assembly Biosciences, Inc

Day range

$19.58 – $20.55

Open

$20.32

Prev close

$19.92

Volume

133.5K

Market cap

$405.58M

Shares out

20.36M

P/E

—

P/S

5.42

P/B

1.33

P/FCF

—

ROE

-0.0%

ROA

-0.0%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 3, 2026

• Annual meeting resultsJun 5, 2026

  On June 4, 2026, the matters listed below were submitted to a vote of the Company's stockholders at the Annual Meeting through the solicitation of proxies. The stockholders elected of the following to serve on the Company's Board of Directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Anthony E. Altig; Tomas Cihlar, Ph.D.; Gina Consylman; Robert D. Cook II; Sir Michael Houghton, Ph.D.; Lisa R. Johnson-Pratt, M.D.; Susan Mahony, Ph.D.; John G. McHutchison, A.O., M.D.; and Jason A. Okazaki.

• Warrant or conversionMay 26, 2026

  The Company granted the Underwriters a 30-day option to purchase up to 566,040 additional shares of Common Stock on the same terms as the Offering Shares, and the Underwriters exercised the option in full on May 22, 2026. Pre-Funded Warrants to purchase up to an aggregate of 415,000 shares of Common Stock were issued with an initial exercise price of $0.001 per share and became immediately exercisable on the date of issuance.

• Product or service launchMay 22, 2026

  Assembly Biosciences, Inc. (the 'Company') issued a press release announcing its plans to expand the clinical development of ABI-6250 ('6250'), its oral entry inhibitor candidate for chronic hepatitis delta virus ('HDV') infection, into primary biliary cholangitis ('PBC') and primary sclerosing cholangitis ('PSC'), broadening the program into cholestatic liver diseases.

• Executive compensation changeMar 30, 2026

  Also on March 24, 2026, the Committee approved an increase to the bonus target for Jason A. Okazaki, the Company's Chief Executive Officer and President, from 60% to 65% of his base salary (the 'Bonus Target Increase'), which is reflected in Amendment No. 1 to Mr. Okazaki's employment agreement. The Bonus Target Increase is effective for fiscal year 2026.

• Clinical trial resultsDec 8, 2025

  The Company announced interim results from the Phase 1b portions of its ongoing Phase 1a/b clinical studies evaluating ABI-1179 and ABI-5366, both investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates for recurrent genital herpes. For ABI-1179, a 98% reduction in HSV-2 shedding rate compared to placebo (p<0.01) was observed with the 50 mg weekly dose, and a 91% reduction in virologically confirmed genital lesion rate was observed.

Days to cover

11.1

Short interest

2.91M

Avg volume

263.1K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks
  positiveZacks Investment Research· Sep 9, 2026
• Assembli to Produce Big Ten Conference Activation at Fanatics Fest in New York
  positiveGlobeNewswire Inc.· Jul 16, 2026
• Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
  positiveGlobeNewswire Inc.· May 11, 2026
• Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
  positiveGlobeNewswire Inc.· May 7, 2026
• Assembly’s NeosAI, Powered by Microsoft Azure AI Foundry, Sets New Benchmark for Legal Productivity—Backed by Real-World Results
  positiveGlobeNewswire Inc.· May 21, 2025